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Abstract
Prostate-specific membrane antigen (PSMA) is a promising target for imaging diagnostics and targeted radionuclide therapy
(theranostics) of prostate cancer and its metastases. There is increasing evidence of encouraging response rates and a low toxicity
profile of radioligand therapy (RLT) of metastatic castration-resistant prostate cancer using 177Lu-labeled PSMA ligands. In this
article, we review the current status of diagnostics and therapy using radiolabeled PSMA ligands. We also suggest protocols for
patient selection criteria and conduct of PSMA-based RLT. Challenges and opportunities of PSMA theranostics are discussed.
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Introduction
Most deaths related to prostate cancer (PC) are due to
advanced disease, which results from any combination of
lymphatic, blood, or contiguous local spread. Targeted radio-
nuclide therapy is an attractive and quickly developing ther-
apy option for a variety of cancers, such as lymphoma,
melanoma, and neuroendocrine tumor.1-4 Prostate-specific
membrane antigen (PSMA), also known as folate hydrolase
I or glutamate carboxypeptidase II, is a type II, 750-amino
acid transmembrane protein (100-120 kDa), which is
anchored in the cell membrane of prostate epithelial cells.
The PSMA is highly expressed on prostate epithelial cells
and strongly upregulated in PC. The PSMA expression seems
correlated to androgen independence, the presence of metas-
tases, and PC progression.5 Despite its name, PSMA is not
specific to the prostate gland and is expressed in other
normal (eg, salivary glands, duodenal mucosa, subset of
proximal renal tubular cells, and subpopulation of neuroen-
docrine cells in the colonic crypts) and neoplastic (eg, sub-
types of transitional cell carcinoma, renal cell carcinoma,
colon carcinoma, and peritumoral and endotumoral endothe-
lial cell of neovasculature) tissues.6-8 There is no known
natural ligand for PSMA, and the reasons for its upregulation
in PC remains unknown. The PSMA ligands undergo consti-
tutive cell internalization by PSMA, which, therefore, repre-
sents an appealing molecular target for theranostics in
metastatic PC.9
PSMA-Based Imaging
Anti-PSMA Antibodies
The first commercialized anti-PSMA antibody was 111In-
capromab-pendetide (ProstaScint, AYTU Bioscience, Engle-
wood, USA),10 which was approved by the US Food and Drug
Administration in 1996. However, ProstaScint was only able to
bind to the intracellular epitope of PSMA and was therefore not
capable of visualizing viable PC cells leading to poor clinical
performance.11
In contrast to 111In-capromab-pendetide, J591 binds to the
extracellular domain of PSMA. Labeled with 111In, J591 can be
used for scintigraphy12 and when labeled with 89Zr for positron
emission tomography (PET).13,14 Recently, 89Zr-Df-IAB2M
was introduced as an anti-PSMA minibody.15 Despite good
tumor detection rates and contrast in scintigraphy,16 J591 as
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well as other radiolabeled antibodies present with limitations
such as low tumor penetrability, long delay between injection
and imaging, nonspecific accumulation associated with inflam-
mation, and high radiation exposure due to the necessity of
radionuclides with long half-lives due to the long plasma
half-life of antibodies.
Small-Molecule PSMA Inhibitors
Small-molecule inhibitors have been developed over the past
2 decades.17-27 The basic chemical structure of the majority
of small-molecule PSMA ligands consists of glutamate–
urea–lysine dimers. This structure derives from hydroxypho-
sphinyl derivatives described by Jackson et al in 1996.17
Another significant step forward was the development of
urea-based inhibitors by Kozikowski et al21,23 as well as the
inhibition of PSMA by phosphonamidothionate derivatives
of glutamic acid.28 One attribute of small-molecule inhibitors
that has a significant impact on imaging and therapy is the
feature that these ligands are internalized into the cells after
binding to PSMA.
Small-Molecule PSMA Inhibitors for Scintigraphy
123I- (MIP)-1072 and 123I-MIP-1095 were the first small-
molecule PSMA inhibitors that were introduced into the
clinic in 2008 by Molecular Insight Pharmaceuticals, Inc
(MIP, now a subsidiary of Progenics Pharmaceuticals Inc,
Cambridge, Massachusetts, USA).24,29 These ligands
demonstrated for the first time the enormous potential of
PSMA ligands for imaging and therapy of PC.25,30 The
subsequent replacement of 123I by 131I led to the first human
therapy with PSMA ligands.31,32 However, the widespread
availability and use of 99mTc made the development of
99mTc-labeled PSMA ligands a desirable pursuit. MIP-1404
and MIP-1405 were the first 99mTc-labeled PSMA ligands,
which were introduced into the clinic in 2010.26,33 Although
both ligands presented with promising results,25 99mTc-MIP-
1404 was chosen to enter further clinical studies due to its
lower urinary excretion.34,35 Currently, 99mTc-MIP-1404 is
the subject of a phase 3 clinical trial designed to evaluate its
sensitivity and specificity to detect PC compared to
histopathology (ClinicalTrials.gov Identifier: NCT02615067).
PSMA Ligands for PET Imaging
The development of PSMA ligands for PET imaging dates back
to as early as 2002. The first tracer published was 11C-MCG
which was used in animal studies.22 The clinical breakthrough
of PET imaging with PSMA ligands was achieved with the
invention of 68Ga-PSMA-11 (also called HBED-CC, HBED,
PSMA-HBED, or Prostamedix), which demonstrated excellent
characteristics.36-38 Since its clinical introduction in May 2011,
PET imaging with 68Ga-PSMA-11 has spread rapidly world-
wide and is regarded as a significant step forward in the diag-
nosis of recurrent PC.38-44 The first publications indicated that
this novel method is significantly superior compared to alterna-
tive methods used for the detection of recurrent PC.36,38 Later
publications confirmed the high sensitivity and specificity of
68Ga-PSMA-11 PET/computed tomography (CT).38-44 68Ga-
PSMA-11 PET/CT is usually conducted at 1 hour post injection
(p.i.) according to its first described clinical setup.37 However,
experience showed that most PC lesions present with increased
uptake and contrast at later imaging timings (3 hours p.i.),
despite the relatively short half-life of 68 Ga.37 Later publica-
tions confirmed these findings.45-47 Alternative PSMA ligands
such as 18F-DCFPyL, 68Ga-PSMA-617, 68Ga-PSMA I&T, or
124I-MIP-1095 demonstrated similar characteristics.31,48-50
Several studies with large patient cohorts have analyzed the
sensitivity of 68Ga-PSMA-11 PET/CT as well as possibly inter-
acting factors such as prostate specific antigen (PSA), injected
amount of tracer, androgen deprivation therapy (ADT), or
Gleason Score (GS).39-41 As expected, the probability to detect
tumor lesions (sensitivity) increased with the PSA value. At
PSA values less than 0.5 ng/mL, the reported detection prob-
ability was about 50%. This rate is assumed to be the highest
among all methods for imaging recurrent PC. However, as
shown in Figure 1, a continuous increase in PSA level does
Figure 1. Probability of a pathologic 68Ga-PSMA-11 PET/CT as his-
togram (A) and plot of the rates of pathologic scans with confidence
intervals (B) depending on PSA (ng/mL) in a cohort of 971 patients.
Reprinted from Afshar-Oromieh et al40 with the permission of the
authors. Ct indicates computed tomography; PET, positron emission
tomography; PSMA, prostate-specific membrane antigen.
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not always correlate with an increase in tumor detection. Even
in the subcohort of patients with PSA levels above 10 ng/mL,
not all patients presented with a pathologic 68Ga-PSMA-11
PET/CT. Absent or low PSMA expression as well as small
tumor size could be possible reasons for this observation. No
association was found between the probability of a pathologic
scan and either of age, injected tracer activity, faster PSA dou-
bling times, or faster PSA velocity. No significant association
but only a tendency was found between higher GS and a higher
probability of a pathologic scan.39,40 In contrast to GS, an
ongoing ADT at the time of the scans was significantly asso-
ciated with a pathologic 68Ga-PSMA-11 PET/CT39,40 although
such a therapy can cause a reduction in tumor size as well as
PSA values. Both of these effects usually entail a negative
impact on tumor detection. It is known from preclinical litera-
ture that ADT can increase the PSMA expression in PC
cells.51,52 On the other hand, another reason for the fact that
patients with ADT more often showed pathological findings in
the 68Ga-PSMA-11-PET/CT could be that ADT is often started
in cases of advanced tumor stages. According to the current
knowledge, there is no need to pause an ADT prior to a PSMA
ligand scan.
The PSMA is not specific for PC. Since the late 1990s, it is
also well-known that the neovasculature of many solid tumors
may express PSMA as well.53 This is reflected by multiple case
reports describing PET-positive nonprostatic tissues.8 How-
ever, in case of recurrent PC, 68Ga-PSMA-11 PET/CT has
showed an excellent specificity.39,54,55
Recently, 18F-labeled PSMA-ligands were clinically intro-
duced with promising results such as DCFBC, DCFPyL, or
PSMA-1007.48,56-58 They all show promising first results. In
theory, 18F-labeled tracers present with advantages such as
higher physical resolution and high amounts of 18F deriving
from cyclotrons. However, future studies will show whether
these theoretical advantages can outweigh the
faster pharmacokinetics and excellent tumor contrast of
68Ga-PSMA-11.
PSMA-Targeted Therapy
After rather unsuccessful therapy with 90Y-CYT-356 monoclo-
nal antibody (mAb) that binds to the intracellular domain of
PSMA,59 the phase 1 and 2 clinical trials utilizing radiolabeled
(177Lu or 90Y) PSMA mAb J591, which targets the extracellu-
lar domain and then gets internalized through endocytosis,
have shown promising results,16,60-62 however, with higher
ratio of irreversible hematological toxicity. Tagawa et al60
treated 47 patients with 177Lu-PSMAmAb J591. They reported
grade 4 thrombocytopenia in 46.8% of patients (29.8%
received platelet transfusions), and a total of 25.5% patients
experienced grade 4 neutropenia. Monoclonal antibodies are
large molecules and therefore show poor permeability in solid
tumors and slow clearance from the circulation, which is prob-
ably the cause of grade 4 hematotoxicity. Instead of mAb,
Maresca et al described the design and synthesis of a series
of small-molecule inhibitors of PSMA.24 First clinical
experiences with PSMA-based radionuclide treatment using
131I-labeled PSMA ligands showed promising results with mild
hematotoxicity and a PSA decrease >50% in 60% of treated
patients with PC.31,32 The 131I has a long half-life of 8.02 days
and with maximum b-particle range of 2.4 mm in soft tissue.
Due to the g-emitting properties and long half-life, 131I is less
attractive from a radiation safety point of view. The 177Lu has a
half-life of 6.7 days and low-energy b-particles emission with a
mean range of 0.7 mm and maximum range of 2.1 mm in soft
tissue.63
Current Status of PSMA-Targeted Radioligand Therapy
Table 1 shows a list of current therapy molecules already
administered in humans. In the first cohort of 10 patients, mild
side effects and considerable rates of PSA response were
reported after 1 cycle of radioligand therapy (RLT) with
177Lu PSMA-617.64 A decline in PSA was observed in 70%
of patients, with more than 50% decline in a few patients.
Another recently published study showed the safety and
favorable therapy response in a larger cohort of 24 patients
who received up to 2 cycles of 177Lu PSMA-617. Twenty-two
patients received 2 cycles of RLT. Eight weeks after the sec-
ond cycle of 177Lu PSMA-617 therapy, 15 (68.2%) of
22 patients experienced a PSA decline compared to the base-
line PSA value, of who 15 experienced a decline of more than
30% and 13 a decline of more than 50%.65 Relevant hemato-
toxicity (grade 3) occurred during the observation period
(within 2 months after the last cycle) in 2 patients only. Apart
from minor grade 1 or 2 hematotoxicity, the majority of
patients did not have any hematotoxicity during the observa-
tion period. No relevant nephrotoxicity or hepatotoxicity was
observed. The overall survival benefit of RLT in comparison
to a historical control group could be demonstrated in
another investigation.66 The estimated median survival was
29.4 weeks in the group treated with 177Lu PSMA-617, which
was noticeably longer than survival in a historical control
group with 19.7 weeks (hazard ratio: 0.44; 95% confidence
interval: 0.20-0.95; P ¼ .031).
Baum et al presented similar results using 177Lu PSMA-
I&T67 treating 56 patients with metastasized PC at an early
stage of castration resistance. Any PSA decline and a decline
of 50% were reported in 80% and a median overall survival
of 13.7 months. In this cohort, prior chemotherapy was
Table 1. PSMA Ligands for Therapy.
Ligand Radionuclide Statusa
MIP-1095 Iodine-131 Compassionate use
PSMA-I&T Lutetium-177 Compassionate use
J591 Lutetium-177 Phase I
PSMA-617 Lutetium-177 Phase I/phase II/phase III
Abbreviations: MIP, Molecular Insight Pharmaceuticals; PSMA, prostate-specific
membrane antigen.
aStatus of use according clinicaltrials.gov.
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performed in 25% of patients. Prior therapy with abiraterone
was performed in 21% and prior enzalutamide was given in
11% of patients, whereas in the prior study mentioned earlier,
pretreatments with chemotherapy, abiraterone, and enzaluta-
mide were administered in 78%, 75%, and 86% of patients,
respectively.66
Results of the abovementioned studies were confirmed by
the findings of the German multicenter study including 145
patients with metastatic castration-resistant PC. Biochemical
response was defined by the PC work group as a PSA decline
50%.68 A PSA decline 50% and any PSA decline were
reported in 45% and 60% of the patients.69 The presence of
visceral metastases and an alkaline phosphatase 220 U/L
were negative predictors of therapy response. Adverse events
were analyzed according to common toxicity criteria. Grade
3 to 4 toxicities such as anemia, leukopenia, and thrombocy-
topenia were reported in 10%, 3%, and 4% of patients treated
with 177Lu PSMA-617. Mild or transient xerostomia were
reported in 8% of the patients. Repeated cycles of 177Lu
PSMA-617 RLT can be performed after radionuclide therapy
using 223Ra dichloride, without a higher probability of hema-
totoxicity.69 These results about the safety and toxicity were
confirmed by another study including 49 patients who
were treated with 3 cycles of 177Lu-PSMA-617. The patients
were separated into 2 groups subjected to a history of prior
therapy with 223Ra. Group 1 included 20 patients who had
received therapy with 223Ra prior to 177Lu-PSMA-617 ther-
apy. Group 2, which was the control group, comprised 29
patients without any history of a bone-targeted radionuclide
therapy. No grade 4 hematotoxicity was observed in
the entire study population. There were no significant
differences between the 2 groups regarding leukopenia and
thrombocytopenia.70 Figure 2A and B shows a case of a
66-year-old patient with metastasized castration-resistant
PC with an excellent response to 177Lu PSMA-617 RLT with
history of prior 223Ra dichloride therapy.
Although there is a specific renal binding of PSMA-ligands,
no grade 3 to 4 toxicities were reported after the RLT. Only
low-grade renal toxicity has been reported so far.71 Table 2
presents reported toxicities of 177Lu-PSMA RLT.
Yordanova et al analyzed changes in creatinine, cyctatin C,
glomerular filtration rate, and tubular function assessed by
99mTc-MAG3 renal scintigraphy in 55 patients receiving at
least 3 (range 3-6) consecutive cycles of 177Lu PSMA-617
every 8 weeks. Significant negative predictor for renal func-
tion were age (>65 years), arterial hypertension, and prior
renal failure.
Two recently published studies75,76 analyzed overall sur-
vival in patients receiving up to 8 cycles of 177Lu PSMA-617
RLT. Any PSA decline after the first cycle was a significant
prognosticator of survival in both studies (68 vs 33 weeks
reported by the first mentioned study and 59 vs 28 weeks
reported by the second-listed study). These results could be
confirmed by a larger 2-center study in patients pretreated
with at least 1 line of chemotherapy and abiraterone and/or
enzalutamide.77 The PSA decline of at least 20.87% was the
optimal parameter in predicting improved overall survival in
the multivariate analysis. The same study group also showed
that in patients who do not respond to the first cycle, further
therapy cycles should be performed, because nearly one-third
Figure 2. A, 68Ga-PSMA11-PET images of a 66-year-old patient with castration-resistant prostate cancer pretreated with docetaxel, abir-
aterone, and 6 cycles of 223Radium. Maximum intensity projection (MIP) on the left side shows multiple bone and lymph node lesions. Patient was
treated with 3 cycles of 177Lu-PSMA-617 radioligand therapy with a cumulative activity of 13.5 GBq (reduced activity because of single kidney).
The MIP images on the right side show significant reduction in prostate-specific membrane antigen (PSMA)-positive lesions in correlation with a
PSA decline of 99%. B, Fused images of 68Ga-PSMA11-positron emission tomography/computed tomography (PET/CT) images in the upper row
show a significant reduction in PSMA-positive lesions. Low-dose CT images (lower row) show a significant volume reduction in soft tissue
lesions (especially in the right pelvis).
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of the patients showed a delayed response after additional
therapy cycles.78
According to currently available results, 177Lu PSMA-617 is
a new and promising therapy option for patients with metastatic
PC, but it has not yet reached clinical approval. It should there-
fore mostly be offered to patients as a salvage therapy; how-
ever, a more upfront role of RLT with PSMA ligands leading to
regulatory approval would seem prudent.
In the following, we summarize the current therapy protocol
most widely used.
Indications for RLT With 177Lu-PSMA-617
 metastatic castrate-resistant PC with PSMA-positive
metastatic disease upon PSMA-PET or single-
photon emission computed tomography (SPECT)
imaging;
 after initial hormone therapy (luteinizing hormone-
releasing hormone agonists/antagonists):
 progressive disease, despite newly developed hor-
mone therapies (abiraterone / enzalutamide)
 progressive disease, despite (first line or second line)
chemotherapy (docetaxel and cabazitaxel) or patient
not suitable for chemotherapy
 not suitable for 223Ra-dichloride due to visceral metas-
tases or diffuse bone marrow metastases; and
 decision for salvage PSMA therapy at the institutional
interdisciplinary tumor board.
Preparation Prior to RLT
 PSMA-PET or SPECT imaging to verify PSMA positive
lesions.
 Renal scintigraphy to evaluate renal function and rule
out obstructive dysfunction, which should be treated
prior to the RLT
Prerequisites for RLT
 White blood cells  2 tsd/mL.
 Hb  8 g/dL, in the case of symptomatic anemia a red
blood cell transfusion should precede the therapy. The
RLT with 177Lu-PSMA-617 may have a positive effect
on bone marrow depression because of tumor regression
in bone marrow.79
 Platelets  75  109/L.
 Creatinine < 2 mg/dL.
 Eastern Cooperative Oncology Group 2.
Proposed Protocol
 Cooling the salivary glands from 30 minutes before
and up to 4 hours after the 177Lu-PSMA-617 injection
for reducing the risk of salivary glands radiation
injuries.
 Using urinary catheter in incontinent patients in the first
48 hours for avoiding any contamination.
 A dose of 6 to 7.4 GBq 177Lu-PSMA-617.
 Injection intravenously as a slow bolus (over about
30 seconds) followed by 1000 mL Ringer or NaCl.
 Four to 6 cycles of the RLT every 6 to 8 weeks.
Follow-Up After RLT
 The PSMA-PET or SPECT imaging before first cycle to
confirm PSMA-positive metastatic disease and after the
last cycle (interim imaging should also be performed if
needed).
 Laboratory test after RLT should be performed every
2 weeks: blood cell counts, creatinine, and liver
panel.
 Decision to pursue the RLT depending on the imaging
and clinical situation.
Table 2. Safety of 177Lu-PSMA radioligand therapy in the literature.
Hematotoxicity CTCAE grade 3/4
Reference n Hb (%) WBC (%) Plt (%) Xerostomia Nonhematologic AE
Ahmadzadehfar et al.64 10 10 0 0 0 mild nausea, fatigue
Rahbar et al.66 28 11 0 0 14 mild nausea
Ahmadzadehfar et al.65 24 9 0 0 8.7 mild nausea
Baum et al.67 56 0 0 0 3.5 na
Kratochwil et al.72 30 3.3 0 3.3 6.7 mild nausea, fatigue
Rahbar et al.73 82 2.8 0 0 8.5 mild nausea
Heck et al.74 22 0 0 0 37 fatigue, appetite loss
Rahbar et al.69 145 10 3 4 8 mild nausea
Bra¨uer et al.75 59 18 3 3 25 nausea, fatigue
Abbreviations: CTCAE: common toxicity criteria of adverse events, Hb: haemoglobin, WBC: white blood cells, Plt: platlets.
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Future Perspectives and Remaining Issues
The PSMA-based imaging and RLT is a theranostic approach,
which is currently applied in metastatic castration–resistant PC.
Radioligand therapy with 177Lu-PSMA-617 seems to be a pro-
mising treatment for metastatic patients with PC. Despite very
encouraging early results, several issues will need to be
resolved to clarify and establish the exact role of PSMA-
based theranostics in PC. With regard to imaging, currently a
number of different agents are available, and the most suitable
agent from the point of view of optimal imaging characteristics,
availability, access, and cost will need to be identified. Similar
notion holds for RLT with b- or a-particles and the specific
clinical situations, which may be best amenable for either type
of particles or both. Using this therapy, as a combination with
newer antiandrogenic drugs such as abiraterone and enzaluta-
mide, at earlier stages of the therapy must be evaluated in
future studies. Larger prospective multicenter studies are
needed to evaluate the potential of RLT among and with other
available therapy options. Moreover, the long-term results
and toxicities must be analyzed after longer follow-up peri-
ods. We have to point out that while preliminary protocols
have been devised, both the imaging and the therapy protocols
will evolve in time as experience with PSMA theranostics
grows. An expanded understanding of the effects of various
treatments on PSMA expression will be needed to facilitate
therapy response assessment. It has been recognized that ADT
increases PSMA expression which is not only relevant in
recognition of posttreatment PSMA PET imaging changes but
also suggests the possibility of synergistic therapeutic effect
of androgen deprivation and PSMA-based RLT. Determina-
tion of the impact of PSMA theranostics on various outcome
measures and comparative cost–benefit analysis will need
investigations.
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